Jean-Charles Nault, Jessica Zucman-Rossi  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 46, Issue 3, Pages (March 2007)
Inflammasomes in liver diseases
Lipotoxicity in NASH Journal of Hepatology
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Volume 149, Issue 4, Pages (October 2015)
Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials  Pippa Newell, Augusto Villanueva, Josep M. Llovet 
Volume 152, Issue 5, Pages (April 2017)
Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, Yujin Hoshida 
Volume 149, Issue 4, Pages (October 2015)
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
The inflammasome in liver disease
Reactive oxygen species in the normal and acutely injured liver
Obesity, inflammation, and liver cancer
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Potential pathways directly linking obesity with cancer.
Liver regeneration Journal of Hepatology
Volume 52, Issue 3, Pages (March 2010)
Thoetchai (Bee) Peeraphatdit, Douglas A. Simonetto, Vijay H. Shah 
NS5A inhibitors in the treatment of hepatitis C
Lipotoxicity in NASH Journal of Hepatology
IL-6 pathway in the liver: From physiopathology to therapy
Volume 120, Issue 1, Pages (January 2001)
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Hepatitis B and C virus-related carcinogenesis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Fig. 2. Functions of NOD-like receptors
Living donor liver transplantation: is the hype over?
JAK inhibitors in dermatology: The promise of a new drug class
Volume 69, Issue 2, Pages (August 2018)
The place of downstaging for hepatocellular carcinoma
P38 Mitogen Activated Protein Kinase Mediates Both Death Signaling and Functional Depression in the Heart  Meijing Wang, MD, Ben M. Tsai, MD, Mark W.
European Association for the Study of the Liver  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt 
Signalling pathways in alcohol-induced liver inflammation
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Biomarkers of liver cell death
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Why men are at higher risk for hepatocellular carcinoma?
Genomic risk of hepatitis C-related hepatocellular carcinoma
Autophagy in the liver Journal of Hepatology
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn 
Hepatitis B and C virus-related carcinogenesis
Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Nanna Fyhrquist, Sampsa Matikainen, Antti Lauerma 
Figure 3 Bile acid-induced hepatic inflammation and carcinogenesis
Signalling links in the liver: Knitting SOCS with fat and inflammation
Chetana Lim, Chady Salloum, Daniel Azoulay
Evolution of liver transplantation for hepatocellular carcinoma
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
Therapeutic strategies in inflammasome mediated diseases of the liver
Volume 44, Issue 5, Pages (May 2006)
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Volume 62, Issue 3, Pages (March 2015)
Pathogenesis of cholestatic hepatitis C
A possible mechanism of renal cell death after ischemia/reperfusion
Immunoregulatory role of TNFα in inflammatory kidney diseases
Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments  László Maródi, MD, PhD, Jean-Laurent.
Genetics of hepatocellular carcinoma: The next generation
Volume 67, Issue 5, Pages (November 2017)
Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?
Macrophages, Immunity, and Metabolic Disease
Volume 66, Issue 3, Pages (March 2017)
Tumor necrosis factor: Biology and therapeutic inhibitors
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Different signaling pathways of TLR2, Nod, and TNFR1 in response to ligand, resulting in activation of NF-κB, the nuclear transcriptional factor responsible.
Presentation transcript:

Building a bridge between obesity, inflammation and liver carcinogenesis  Jean-Charles Nault, Jessica Zucman-Rossi  Journal of Hepatology  Volume 53, Issue 4, Pages 777-779 (October 2010) DOI: 10.1016/j.jhep.2010.05.011 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Implication of IL-6 and TNFα pathway in obesity related hepatocarcinogenesis. NASH, non-alcoholic steatohepatitis; IL-6, interleukin 6; TNFα, tumor necrosis factor α; IL-6R, IL-6 receptor; JAK ½, janus kinase 1 and 2; gp130, glucoprotein 130; STAT3, signal transducer and activator of transcription 3; APRE, acute phase response element; TNFR1/2, TNF receptor 1 and 2; TRADD, tumor necrosis factor receptor type 1-associated DEATH domain protein; TRAF2, TNF receptor-associated factor 2; MAPK, mitogen-activated protein kinase; NF-kappaβ, nuclear factor Kβ; DEN, diethylnitrosamine; OH, alcohol; HCC, hepatocellular carcinoma; Mϕ, macrophage. Journal of Hepatology 2010 53, 777-779DOI: (10.1016/j.jhep.2010.05.011) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions